Avicins comprise a class of
triterpenoid compounds that exhibit
tumor inhibitory activity. Here we show that
avicin G is inhibitory to growth of the fission yeast Schizosaccharomyces pombe. S. pombe cells treated with a lethal concentration of
avicin G (20 microM) exhibited a shrunken morphology, indicating that
avicin G adversely affects cell integrity. Cells treated with a sublethal concentration of
avicin G (6.5 microM) exhibited a strong cytokinesis-defective phenotype (multiseptated cells), as well as cell morphology defects. These phenotypes bear resemblance to those resulting from loss of Rho1
GTPase function in S. pombe. Indeed, Rho1-deficient S. pombe cells were strongly hypersensitive to
avicin G, suggesting that the compound may perturb Rho1-dependent processes. Consistent with previously observed effects in human Jurkat T cells,
avicin G treatment resulted in hyperaccumulation of
ubiquitinated proteins in S. pombe cells. Interestingly,
proteasome-defective S. pombe mutants were not markedly hypersensitive to
avicin G, whereas an
anaphase-promoting complex (mitotic
ubiquitin ligase) mutant exhibited
avicin G resistance, suggesting that the increase in levels of
ubiquitinated proteins resulting from
avicin G treatment may be due to increased
protein ubiquitination, rather than inhibition of
26S proteasome activity. Mutants defective in the cAMP/PKA pathway also exhibited resistance to
avicin G. Our results suggest that S. pombe will be a useful model organism for elucidating molecular targets of
avicin G and serve as a guide to clinical application where dysfunctional aspects of Rho and/or ubiquitination function have been demonstrated as in
cancer,
fibrosis, and
inflammation.